APO Research
Talk to an analyst

APO RESEARCH · REPORT

Remicade (Infliximab) and Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Remicade (Infliximab) and Biosimilar Market Outlook and Growth Opportunities 2026

20 December 2025195 pages

Choose your research edition.

Industry ResearchRemicade (Infliximab) and Biosimilar Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Remicade (Infliximab) and Biosimilar Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Remicade (Infliximab) and Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Remicade (Infliximab) and Biosimilar Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Remicade (Infliximab) and Biosimilar Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Remicade (Infliximab) and Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Remicade (Infliximab) and Biosimilar market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Remicade (Infliximab) and Biosimilar market include J & J, Pfizer, Amgen and Organon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Remicade (Infliximab) and Biosimilar market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Remicade (Infliximab) and Biosimilar and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Remicade (Infliximab) and Biosimilar sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Remicade (Infliximab) and Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.

Remicade (Infliximab) and Biosimilar Segment by Company

J & J

Pfizer

Amgen

Organon

Remicade (Infliximab) and Biosimilar Segment by Type

Brand

Biosimilar

Remicade (Infliximab) and Biosimilar Segment by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Other

Remicade (Infliximab) and Biosimilar Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Remicade (Infliximab) and Biosimilar status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Remicade (Infliximab) and Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Remicade (Infliximab) and Biosimilar significant trends, drivers, influence factors in global and regions.

6. To analyze Remicade (Infliximab) and Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade (Infliximab) and Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Remicade (Infliximab) and Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade (Infliximab) and Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Remicade (Infliximab) and Biosimilar market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Remicade (Infliximab) and Biosimilar industry.

Chapter 3: Detailed analysis of Remicade (Infliximab) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Remicade (Infliximab) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Remicade (Infliximab) and Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Remicade (Infliximab) and Biosimilar Industry Trends Table 2. Remicade (Infliximab) and Biosimilar Industry Drivers Table 3. Remicade (Infliximab) and Biosimilar Industry Opportunities and Challenges Table 4. Remicade (Infliximab) and Biosimilar Industry Restraints Table 5. Global Remicade (Infliximab) and Biosimilar Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Remicade (Infliximab) and Biosimilar Revenue Share by Company (2021-2026) Table 7. Global Remicade (Infliximab) and Biosimilar Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Company (2021-2026) Table 9. Global Remicade (Infliximab) and Biosimilar Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Remicade (Infliximab) and Biosimilar Company Ranking, (2024-2026) & (USD Million) Table 11. Global Remicade (Infliximab) and Biosimilar Key Company Manufacturing Base & Headquarters Table 12. Global Remicade (Infliximab) and Biosimilar Company, Product Type & Application Table 13. Global Remicade (Infliximab) and Biosimilar Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Remicade (Infliximab) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Brand Table 18. Significant Companies of Biosimilar Table 19. Global Remicade (Infliximab) and Biosimilar Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Remicade (Infliximab) and Biosimilar Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Remicade (Infliximab) and Biosimilar Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Type (2021-2026) Table 23. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Type (2027-2032) Table 24. Global Remicade (Infliximab) and Biosimilar Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Remicade (Infliximab) and Biosimilar Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Remicade (Infliximab) and Biosimilar Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Type (2021-2026) Table 28. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Ankylosing Spondylitis Table 30. Significant Companies of Rheumatoid Arthritis Table 31. Significant Companies of Crohn’s Disease Table 32. Significant Companies of Other Table 33. Global Remicade (Infliximab) and Biosimilar Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Remicade (Infliximab) and Biosimilar Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Remicade (Infliximab) and Biosimilar Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Application (2021-2026) Table 37. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Application (2027-2032) Table 38. Global Remicade (Infliximab) and Biosimilar Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Remicade (Infliximab) and Biosimilar Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Remicade (Infliximab) and Biosimilar Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Application (2021-2026) Table 42. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Application (2027-2032) Table 43. Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Remicade (Infliximab) and Biosimilar Sales by Region (2021-2026) & (K Units) Table 45. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2021-2026) Table 46. Global Remicade (Infliximab) and Biosimilar Sales by Region (2027-2032) & (K Units) Table 47. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2027-2032) Table 48. Global Remicade (Infliximab) and Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Remicade (Infliximab) and Biosimilar Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Region (2021-2026) Table 51. Global Remicade (Infliximab) and Biosimilar Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Region (2027-2032) Table 53. Global Remicade (Infliximab) and Biosimilar Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Remicade (Infliximab) and Biosimilar Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Remicade (Infliximab) and Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Remicade (Infliximab) and Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Remicade (Infliximab) and Biosimilar Sales by Country (2021-2026) & (K Units) Table 58. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2021-2026) Table 59. Global Remicade (Infliximab) and Biosimilar Sales by Country (2027-2032) & (K Units) Table 60. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2027-2032) Table 61. Global Remicade (Infliximab) and Biosimilar Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Remicade (Infliximab) and Biosimilar Sales Value Market Share by Country (2021-2026) Table 63. Global Remicade (Infliximab) and Biosimilar Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Remicade (Infliximab) and Biosimilar Sales Value Market Share by Country (2027-2032) Table 65. J & J Company Information Table 66. J & J Business Overview Table 67. J & J Remicade (Infliximab) and Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. J & J Remicade (Infliximab) and Biosimilar Product Portfolio Table 69. J & J Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Remicade (Infliximab) and Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio Table 74. Pfizer Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Remicade (Infliximab) and Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Amgen Remicade (Infliximab) and Biosimilar Product Portfolio Table 79. Amgen Recent Development Table 80. Organon Company Information Table 81. Organon Business Overview Table 82. Organon Remicade (Infliximab) and Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Organon Remicade (Infliximab) and Biosimilar Product Portfolio Table 84. Organon Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Remicade (Infliximab) and Biosimilar Distributors List Table 88. Remicade (Infliximab) and Biosimilar Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Remicade (Infliximab) and Biosimilar Product Image Figure 2. Global Remicade (Infliximab) and Biosimilar Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Remicade (Infliximab) and Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 4. Global Remicade (Infliximab) and Biosimilar Sales (2021-2032) & (K Units) Figure 5. Global Remicade (Infliximab) and Biosimilar Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Remicade (Infliximab) and Biosimilar Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Brand Image Figure 10. Biosimilar Image Figure 11. Global Remicade (Infliximab) and Biosimilar Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Remicade (Infliximab) and Biosimilar Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Type (2021-2032) Figure 14. Global Remicade (Infliximab) and Biosimilar Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Remicade (Infliximab) and Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Type (2021-2032) Figure 17. Ankylosing Spondylitis Image Figure 18. Rheumatoid Arthritis Image Figure 19. Crohn’s Disease Image Figure 20. Other Image Figure 21. Global Remicade (Infliximab) and Biosimilar Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Remicade (Infliximab) and Biosimilar Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Application (2021-2032) Figure 24. Global Remicade (Infliximab) and Biosimilar Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Remicade (Infliximab) and Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Application (2021-2032) Figure 27. Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Remicade (Infliximab) and Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Remicade (Infliximab) and Biosimilar Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Remicade (Infliximab) and Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 32. North America Remicade (Infliximab) and Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Remicade (Infliximab) and Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Remicade (Infliximab) and Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Remicade (Infliximab) and Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Remicade (Infliximab) and Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Remicade (Infliximab) and Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 38. South America Remicade (Infliximab) and Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Remicade (Infliximab) and Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Remicade (Infliximab) and Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Remicade (Infliximab) and Biosimilar Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Remicade (Infliximab) and Biosimilar Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Brand
  • Biosimilar
Applications
  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other
Companies covered
  • J & J
  • Pfizer
  • Amgen
  • Organon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Remicade (Infliximab) and Biosimilar Sales Value (2021-2032)
  4. 1.2.2 Global Remicade (Infliximab) and Biosimilar Sales Volume (2021-2032)
  5. 1.2.3 Global Remicade (Infliximab) and Biosimilar Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Remicade (Infliximab) and Biosimilar Market Dynamics
  1. 2.1 Remicade (Infliximab) and Biosimilar Industry Trends
  2. 2.2 Remicade (Infliximab) and Biosimilar Industry Drivers
  3. 2.3 Remicade (Infliximab) and Biosimilar Industry Opportunities and Challenges
  4. 2.4 Remicade (Infliximab) and Biosimilar Industry Restraints
3 Remicade (Infliximab) and Biosimilar Market by Company
  1. 3.1 Global Remicade (Infliximab) and Biosimilar Company Revenue Ranking in 2025
  2. 3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Company (2021-2026)
  3. 3.3 Global Remicade (Infliximab) and Biosimilar Sales Volume by Company (2021-2026)
  4. 3.4 Global Remicade (Infliximab) and Biosimilar Average Price by Company (2021-2026)
  5. 3.5 Global Remicade (Infliximab) and Biosimilar Company Ranking (2024-2026)
  6. 3.6 Global Remicade (Infliximab) and Biosimilar Company Manufacturing Base and Headquarters
  7. 3.7 Global Remicade (Infliximab) and Biosimilar Company Product Type and Application
  8. 3.8 Global Remicade (Infliximab) and Biosimilar Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Remicade (Infliximab) and Biosimilar Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Remicade (Infliximab) and Biosimilar Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Remicade (Infliximab) and Biosimilar Market by Type
  1. 4.1 Remicade (Infliximab) and Biosimilar Type Introduction
  2. 4.1.1 Brand
  3. 4.1.2 Biosimilar
  4. 4.2 Global Remicade (Infliximab) and Biosimilar Sales Volume by Type
  5. 4.2.1 Global Remicade (Infliximab) and Biosimilar Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Remicade (Infliximab) and Biosimilar Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Remicade (Infliximab) and Biosimilar Sales Value by Type
  9. 4.3.1 Global Remicade (Infliximab) and Biosimilar Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Remicade (Infliximab) and Biosimilar Sales Value by Type (2021-2032)
  11. 4.3.3 Global Remicade (Infliximab) and Biosimilar Sales Value Share by Type (2021-2032)
5 Remicade (Infliximab) and Biosimilar Market by Application
  1. 5.1 Remicade (Infliximab) and Biosimilar Application Introduction
  2. 5.1.1 Ankylosing Spondylitis
  3. 5.1.2 Rheumatoid Arthritis
  4. 5.1.3 Crohn’s Disease
  5. 5.1.4 Other
  6. 5.2 Global Remicade (Infliximab) and Biosimilar Sales Volume by Application
  7. 5.2.1 Global Remicade (Infliximab) and Biosimilar Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Remicade (Infliximab) and Biosimilar Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Remicade (Infliximab) and Biosimilar Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Remicade (Infliximab) and Biosimilar Sales Value by Application
  11. 5.3.1 Global Remicade (Infliximab) and Biosimilar Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Remicade (Infliximab) and Biosimilar Sales Value by Application (2021-2032)
  13. 5.3.3 Global Remicade (Infliximab) and Biosimilar Sales Value Share by Application (2021-2032)
6 Remicade (Infliximab) and Biosimilar Regional Sales and Value Analysis
  1. 6.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Remicade (Infliximab) and Biosimilar Sales by Region (2021-2032)
  3. 6.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021-2026
  4. 6.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Region (2027-2032)
  5. 6.3 Global Remicade (Infliximab) and Biosimilar Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Remicade (Infliximab) and Biosimilar Sales Value by Region (2021-2032)
  7. 6.4.1 Global Remicade (Infliximab) and Biosimilar Sales Value by Region: 2021-2026
  8. 6.4.2 Global Remicade (Infliximab) and Biosimilar Sales Value by Region (2027-2032)
  9. 6.5 Global Remicade (Infliximab) and Biosimilar Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Remicade (Infliximab) and Biosimilar Sales Value (2021-2032)
  12. 6.6.2 North America Remicade (Infliximab) and Biosimilar Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Remicade (Infliximab) and Biosimilar Sales Value (2021-2032)
  15. 6.7.2 Europe Remicade (Infliximab) and Biosimilar Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Remicade (Infliximab) and Biosimilar Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Remicade (Infliximab) and Biosimilar Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Remicade (Infliximab) and Biosimilar Sales Value (2021-2032)
  21. 6.9.2 South America Remicade (Infliximab) and Biosimilar Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Remicade (Infliximab) and Biosimilar Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Remicade (Infliximab) and Biosimilar Sales Value Share by Country, 2025 VS 2032
7 Remicade (Infliximab) and Biosimilar Country-level Sales and Value Analysis
  1. 7.1 Global Remicade (Infliximab) and Biosimilar Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Remicade (Infliximab) and Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
  4. 7.3.1 Global Remicade (Infliximab) and Biosimilar Sales by Country (2021-2026)
  5. 7.3.2 Global Remicade (Infliximab) and Biosimilar Sales by Country (2027-2032)
  6. 7.4 Global Remicade (Infliximab) and Biosimilar Sales Value by Country (2021-2032)
  7. 7.4.1 Global Remicade (Infliximab) and Biosimilar Sales Value by Country (2021-2026)
  8. 7.4.2 Global Remicade (Infliximab) and Biosimilar Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Remicade (Infliximab) and Biosimilar Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Remicade (Infliximab) and Biosimilar Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Remicade (Infliximab) and Biosimilar Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 J & J
  2. 8.1.1 J & J Company Information
  3. 8.1.2 J & J Business Overview
  4. 8.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 J & J Remicade (Infliximab) and Biosimilar Product Portfolio
  6. 8.1.5 J & J Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Remicade (Infliximab) and Biosimilar Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Organon
  20. 8.4.1 Organon Company Information
  21. 8.4.2 Organon Business Overview
  22. 8.4.3 Organon Remicade (Infliximab) and Biosimilar Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Organon Remicade (Infliximab) and Biosimilar Product Portfolio
  24. 8.4.5 Organon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Remicade (Infliximab) and Biosimilar Value Chain Analysis
  2. 9.1.1 Remicade (Infliximab) and Biosimilar Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Remicade (Infliximab) and Biosimilar Sales Mode & Process
  6. 9.2 Remicade (Infliximab) and Biosimilar Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Remicade (Infliximab) and Biosimilar Distributors
  9. 9.2.3 Remicade (Infliximab) and Biosimilar Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst